Osteomyelitis: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
Line 11: | Line 11: | ||
**For example, [[vancomycin]] plus [[ceftriaxone]] |
**For example, [[vancomycin]] plus [[ceftriaxone]] |
||
=== |
===Parenteral Antimicrobials=== |
||
{| class="wikitable" |
{| class="wikitable" |
||
!Organism |
!Organism |
||
!Antimicrobial Options |
!Antimicrobial Options |
||
|- |
|- |
||
| rowspan="5" |[[MSSA]] |
|||
⚫ | |||
|[[nafcillin]] 2 g IV q4h |
|||
⚫ | |||
|- |
|- |
||
|[[oxacillin]] 2 g IV q4h |
|||
⚫ | |||
⚫ | |||
|- |
|- |
||
|[[cefazolin]] 2 g IV q8h |
|||
⚫ | |||
| |
|- |
||
|[[flucloxacillin]] 2 g IV q6h |
|||
⚫ | |||
|[[ceftriaxone]] 2 g IV q24h |
|||
⚫ | |||
| rowspan="3" |[[MRSA]] |
|||
|[[vancomycin]] 20 mg/kg load followed by 15-20 mg IV q8-12h |
|||
⚫ | |||
|[[daptomycin]] 6 to 10 mg/kg IV daily |
|||
⚫ | |||
|[[teicoplanin]] 12 mg/kg IV q12h for 3 to 5 doses followed by q24h |
|||
⚫ | |||
| rowspan="2" |Adjunctive staphylococcal agent |
|||
|[[rifampin]] 300 to 450 mg PO bid |
|||
|- |
|||
|[[fusidic acid]] 500 mg PO tid |
|||
|- |
|||
| rowspan="7" |[[Gram-negative bacteria]] |
|||
|[[ciprofloxacin]] 750 mg PO big to 400 mg IV q12h |
|||
|- |
|||
|[[levofloxacin]] 750 mg PO/IV daily |
|||
|- |
|||
|[[ceftriaxone]] 2 g IV q24h |
|||
|- |
|||
|[[ceftazidime]] 2 g IV q8h |
|||
|- |
|||
|[[cefepime]] 2 g IV q8-12h |
|||
|- |
|||
|[[ertapenem]] 1 g IV q24h |
|||
|- |
|||
|[[meropenem]] 1 g IV q8h |
|||
|- |
|||
|[[Pseudomonas aeruginosa]] |
|||
|[[ciprofloxacin]] 400 mg IV q8h |
|||
|- |
|||
| rowspan="8" |[[Enterococcus species]] |
|||
|[[ampicillin]] 12 g continuous IV q24h |
|||
|- |
|||
|[[ampicillin]] 2 g IV q4h |
|||
|- |
|||
|[[penicillin G]] 20 to 24 million units continuous IV q24h |
|||
|- |
|||
|[[penicillin G]] 3-4 million units IV q4h |
|||
|- |
|||
|[[vancomycin]] 20 mg/kg IV load followed by 15 mg/kg IV q12h (max 2 g per dose) |
|||
|- |
|||
|[[daptomycin]] 6 to 10 mg/kg IV daily |
|||
|- |
|||
|[[teicoplanin]] 12 mg/kg IV q12h for 3 to 5 doses, followed by q24h |
|||
|- |
|||
|[[ampicillin]] as above, PLUS [[ceftriaxone]] 2 g IV q12-24h |
|||
|- |
|||
| rowspan="6" |penicillin-susceptible [[streptococci]] |
|||
|[[ampicillin]] 12 g continuous IV q24h |
|||
|- |
|||
|[[ampicillin]] 2 g IV q4h |
|||
|- |
|||
|[[penicillin G]] 20 to 24 million units continuous IV q24h |
|||
|- |
|||
|[[penicillin G]] 3-4 million units IV q4h |
|||
|- |
|||
|[[ceftriaxone]] 2 g IV q24h |
|||
|- |
|||
|[[vancomycin]] 20 mg/kg IV load followed by 15 mg/kg IV q12h (max 2 g per dose) |
|||
|- |
|||
| rowspan="3" |[[Cutibacterium acnes]] |
|||
|[[penicillin G]] 20 to 24 million units continuous IV q24h |
|||
|- |
|||
|[[penicillin G]] 3-4 million units IV q4h |
|||
|- |
|||
|[[ceftriaxone]] 2 g IV q24h |
|||
|} |
|} |
||
=== |
===Oral Antimicrobials=== |
||
{| class="wikitable" |
{| class="wikitable" |
||
!Organism |
!Organism |
Revision as of 13:13, 14 January 2021
Management
- No clinically meaningful differences in bone penetration between classes of antibiotics exist1
- Bioavailability likely still important
- Empiric antimicrobials should generally cover MRSA, susceptible Gram-positives, and common Gram-negatives
- For example, vancomycin plus ceftriaxone
Parenteral Antimicrobials
Organism | Antimicrobial Options |
---|---|
MSSA | nafcillin 2 g IV q4h |
oxacillin 2 g IV q4h | |
cefazolin 2 g IV q8h | |
flucloxacillin 2 g IV q6h | |
ceftriaxone 2 g IV q24h | |
MRSA | vancomycin 20 mg/kg load followed by 15-20 mg IV q8-12h |
daptomycin 6 to 10 mg/kg IV daily | |
teicoplanin 12 mg/kg IV q12h for 3 to 5 doses followed by q24h | |
Adjunctive staphylococcal agent | rifampin 300 to 450 mg PO bid |
fusidic acid 500 mg PO tid | |
Gram-negative bacteria | ciprofloxacin 750 mg PO big to 400 mg IV q12h |
levofloxacin 750 mg PO/IV daily | |
ceftriaxone 2 g IV q24h | |
ceftazidime 2 g IV q8h | |
cefepime 2 g IV q8-12h | |
ertapenem 1 g IV q24h | |
meropenem 1 g IV q8h | |
Pseudomonas aeruginosa | ciprofloxacin 400 mg IV q8h |
Enterococcus species | ampicillin 12 g continuous IV q24h |
ampicillin 2 g IV q4h | |
penicillin G 20 to 24 million units continuous IV q24h | |
penicillin G 3-4 million units IV q4h | |
vancomycin 20 mg/kg IV load followed by 15 mg/kg IV q12h (max 2 g per dose) | |
daptomycin 6 to 10 mg/kg IV daily | |
teicoplanin 12 mg/kg IV q12h for 3 to 5 doses, followed by q24h | |
ampicillin as above, PLUS ceftriaxone 2 g IV q12-24h | |
penicillin-susceptible streptococci | ampicillin 12 g continuous IV q24h |
ampicillin 2 g IV q4h | |
penicillin G 20 to 24 million units continuous IV q24h | |
penicillin G 3-4 million units IV q4h | |
ceftriaxone 2 g IV q24h | |
vancomycin 20 mg/kg IV load followed by 15 mg/kg IV q12h (max 2 g per dose) | |
Cutibacterium acnes | penicillin G 20 to 24 million units continuous IV q24h |
penicillin G 3-4 million units IV q4h | |
ceftriaxone 2 g IV q24h |
Oral Antimicrobials
Organism | Antibiotic Options |
---|---|
MSSA | cefadroxil 500 to 1000 mg PO bid |
cephalexin 500 mg PO tid to qid, or 1000 mg PO bid to tid | |
dicloxacillin 500 mg PO tid to qid | |
flucloxaxillin 500 mg PO tid to qid | |
MRSA | TMP-SMX DS 1 tablet PO bid |
doxycycline 100 mg PO bid | |
minocycline 100 mg PO bid | |
clindamycin 600 mg PO tid | |
Gram-negative bacteria | TMP-SMX DS 1 tablet PO bid |
ciprofloxacin 500 mg PO bid | |
levofloxacin 500 mg PO daily | |
penicillin-susceptible streptococci and enterococci | amoxicillin 500 mg PO bid to tid |
penicillin VK 500 mg PO bid to tid | |
Cutibacterium acnes | amoxicillin 500 mg PO bid to tid |
penicillin VK 500 mg PO bid to tid |
References
- ^ Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.